Please assess the completion status of the following clinical trial:

Trial Title: Varenicline and Bupropion for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is at least 18 years of age;~2. Subject has provide written informed consent;~3. Subject is smoking greater than or equal to 10 cigarettes per day for at least 6 months;~3) Subject is able to complete all study visits 4) Subject is in good health as determined by the investigator 5) Subject has the ability to participate fully in all aspects of the study and keep scheduled appointments 6) Subject is motivated to stop smoking.~Exclusion Criteria:~Female and were pregnant, lactating or likely to become pregnant during the trial and not able nor willing to use contraception or had:~1. an unstable medical condition;~2. another household member participating in the study;~3. bupropion or varenicline allergy;~4. current use (previous 30 days) of a tobacco dependence treatment and unable or unwilling to discontinue use;~5. an unstable medical condition or unstable angina, myocardial infarction, or coronary angioplasty (past 3 months) or an untreated cardiac dysrhythmia;~6. a history of renal failure or were on renal dialysis;~7. a history of seizures;~8. as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale), current non-specific suicidal thoughts or lifetime history of a suicidal attempt (defined as potentially self-injurious act committed with at least some wish to die, as a result of act);~9. a history of closed head trauma associated with \> 30 minutes of loss of consciousness, amnesia, skull fracture, subdural hematoma, or brain contusion;~10. a history or psychosis, bipolar disorder, bulimia or anorexia nervosa;~11. current moderate or severe depression as assessed by a score of ≥ 20 on the Beck Depression Inventory, Second Edition (BDI-II) 10;~12. active substance abuse other than nicotine;~13. current (past 14 days) use of an antipsychotic, monoamine oxidase inhibitors, or drugs known to interact with bupropion SR;~14. a recent dose change of their antidepressant (within last 3 months);~15. untreated hypertension or baseline systolic blood pressure \> 180 or diastolic \> 100;~16. current treatment with another investigational drug for tobacco dependence (previous 30 days); or~17. current use of bupropion or varenicline (previous 30 days).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- varenicline and buproprion SR (Type: ACTIVE_COMPARATOR): Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
- varenicline and placebo (Type: PLACEBO_COMPARATOR): Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.

Based on this trial design, predict the completion outcome and termination type (if applicable).